Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 2001 Feb; 60(2): 116–123.
PMCID: PMC1753477

Autoantibody profiles in the sera of European patients with myositis


OBJECTIVE—To determine the prevalence of myositis specific autoantibodies (MSAs) and several myositis associated autoantibodies (MAAs) in a large group of patients with myositis.
METHODS—A total of 417 patients with myositis from 11 European countries (198 patients with polymyositis (PM), 181 with dermatomyositis (DM), and 38 with inclusion body myositis (IBM)) were serologically analysed by immunoblot, enzyme linked immunosorbent assay (ELISA) and/or immunoprecipitation.
RESULTS—Autoantibodies were found in 232 sera (56%), including 157 samples (38%) which contained MSAs. The most commonly detected MSA was anti-Jo-1 (18%). Other anti-synthetase, anti-Mi-2, and anti-SRP autoantibodies were found in 3%, 14%, and 5% of the sera, respectively. A relatively high number of anti-Mi-2 positive PM sera were found (9% of PM sera). The most commonly detected MAA was anti-Ro52 (25%). Anti-PM/Scl-100, anti-PM/Scl-75, anti-Mas, anti-Ro60, anti-La, and anti-U1 snRNP autoantibodies were present in 6%, 3%, 2%, 4%, 5%, and 6% of the sera, respectively. Remarkable associations were noticed between anti-Ro52 and anti-Jo-1 autoantibodies and, in a few sera, also between anti-Jo-1 and anti-SRP or anti-Mi-2 autoantibodies.
CONCLUSIONS—The incidence of most of the tested autoantibody activities in this large group of European patients is in agreement with similar studies of Japanese and American patients. The relatively high number of PM sera with anti-Mi-2 reactivity may be explained by the use of multiple recombinant fragments spanning the complete antigen. Furthermore, our data show that some sera may contain more than one type of MSA and confirm the strong association of anti-Ro52 with anti-Jo-1 reactivity.

Full Text

The Full Text of this article is available as a PDF (170K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991 Nov 21;325(21):1487–1498. [PubMed]
  • Askanas V, Engel WK. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol. 1998 Nov;10(6):530–542. [PubMed]
  • Reichlin M, Arnett FC., Jr Multiplicity of antibodies in myositis sera. Arthritis Rheum. 1984 Oct;27(10):1150–1156. [PubMed]
  • Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991 Nov;70(6):360–374. [PubMed]
  • Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am. 1994 Nov;20(4):857–880. [PubMed]
  • Allmang C, Petfalski E, Podtelejnikov A, Mann M, Tollervey D, Mitchell P. The yeast exosome and human PM-Scl are related complexes of 3' --> 5' exonucleases. Genes Dev. 1999 Aug 15;13(16):2148–2158. [PMC free article] [PubMed]
  • Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9739–9743. [PMC free article] [PubMed]
  • Low SC, Berry MJ. Knowing when not to stop: selenocysteine incorporation in eukaryotes. Trends Biochem Sci. 1996 Jun;21(6):203–208. [PubMed]
  • Klein Gunnewiek JM, van de Putte LB, van Venrooij WJ. The U1 snRNP complex: an autoantigen in connective tissue diseases. An update. Clin Exp Rheumatol. 1997 Sep-Oct;15(5):549–560. [PubMed]
  • Pruijn GJ, Simons FH, van Venrooij WJ. Intracellular localization and nucleocytoplasmic transport of Ro RNP components. Eur J Cell Biol. 1997 Oct;74(2):123–132. [PubMed]
  • Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum. 1995 Oct;38(10):1389–1399. [PubMed]
  • Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, Akizuki M, Targoff IN. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol. 1999 Feb 15;162(4):2315–2320. [PubMed]
  • Brouwer R, Vree Egberts W, Jongen PH, van Engelen BG, van Venrooij WJ. Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis Rheum. 1998 Aug;41(8):1428–1437. [PubMed]
  • Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med. 1986 May 1;163(5):1281–1291. [PMC free article] [PubMed]
  • Lütcke H, Dobberstein B. Structure and function of signal recognition particle (SRP). Mol Biol Rep. 1993 Aug;18(2):143–147. [PubMed]
  • Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990 Sep;33(9):1361–1370. [PubMed]
  • Leff RL, Burgess SH, Miller FW, Love LA, Targoff IN, Dalakas MC, Joffe MM, Plotz PH. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum. 1991 Nov;34(11):1391–1396. [PubMed]
  • Ge Q, Nilasena DS, O'Brien CA, Frank MB, Targoff IN. Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest. 1995 Oct;96(4):1730–1737. [PMC free article] [PubMed]
  • Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS. Characterization of the CHD family of proteins. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11472–11477. [PMC free article] [PubMed]
  • Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet. 1999 Sep;23(1):62–66. [PubMed]
  • Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999 Aug 1;13(15):1924–1935. [PMC free article] [PubMed]
  • von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323–358. [PubMed]
  • Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000 Jan;43(1):155–163. [PubMed]
  • Hengstman GJ, van Engelen BG, Badrising UA, van den Hoogen FH, van Venrooij WJ. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis. Ann Neurol. 1998 Sep;44(3):423–423. [PubMed]
  • Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 1992 Apr;35(4):449–456. [PubMed]
  • Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, Jablonska S. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997 Jul;40(7):1257–1266. [PubMed]
  • Uthman I, Vázquez-Abad D, Senécal JL. Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum. 1996 Aug;26(1):447–458. [PubMed]
  • Koh ET, Seow A, Ong B, Ratnagopal P, Tjia H, Chng HH. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis. 1993 Dec;52(12):857–861. [PMC free article] [PubMed]
  • Lundberg I, Nennesmo I, Hedfors E. A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies. Semin Arthritis Rheum. 1992 Oct;22(2):127–138. [PubMed]
  • Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum. 1986 Feb;15(3):168–178. [PubMed]
  • Holden DJ, Brownell AK, Fritzler MJ. Clinical and serologic features of patients with polymyositis or dermatomyositis. Can Med Assoc J. 1985 Mar 15;132(6):649–653. [PMC free article] [PubMed]
  • Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985 Dec;12(6):1140–1148. [PubMed]
  • Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum. 1985 Mar;28(3):249–255. [PubMed]
  • Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996 Sep;39(9):1507–1518. [PubMed]
  • Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997 Jul;109(1):32–40. [PMC free article] [PubMed]
  • Hengstman GJ, van Venrooij WJ, Vencovsky J, Moutsopoulos HM, van Engelen BG. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis. 2000 Feb;59(2):141–142. [PMC free article] [PubMed]
  • Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13;292(7):344–347. [PubMed]
  • Okada N, Mimori T, Mukai R, Kashiwagi H, Hardin JA. Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol. 1987 May 15;138(10):3219–3223. [PubMed]
  • Roux S, Seelig HP, Meyer O. Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J Rheumatol. 1998 Feb;25(2):395–396. [PubMed]
  • Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA., Jr Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum. 1992 Oct;35(10):1211–1217. [PubMed]
  • Blüthner M, Bautz FA. Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD protein. J Exp Med. 1992 Oct 1;176(4):973–980. [PMC free article] [PubMed]
  • Ge Q, Frank MB, O'Brien C, Targoff IN. Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest. 1992 Aug;90(2):559–570. [PMC free article] [PubMed]
  • Alderuccio F, Chan EK, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med. 1991 Apr 1;173(4):941–952. [PMC free article] [PubMed]
  • Ge Q, Wu Y, Trieu EP, Targoff IN. Analysis of the specificity of anti-PM-Scl autoantibodies. Arthritis Rheum. 1994 Oct;37(10):1445–1452. [PubMed]
  • Kalovidouris AE. Immune aspects of myositis. Curr Opin Rheumatol. 1992 Dec;4(6):809–814. [PubMed]
  • Miller FW. Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1991 Dec;3(6):902–910. [PubMed]
  • Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun. 1999 Mar;12(2):137–142. [PubMed]
  • Ben-Chetrit E, Fox RI, Tan EM. Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's syndrome. Arthritis Rheum. 1990 Mar;33(3):349–355. [PubMed]
  • Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985 Jul;28(7):796–803. [PubMed]
  • Garlepp MJ. Genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1996 Nov;8(6):514–520. [PubMed]

Figures and Tables

Figure 1
Schematic representation of the Mi-2β autoantigen and the fragments used in ELISA. NT = N-terminal; M = middle; NM = N-terminal/middle; CT = C-terminal.
Figure 2
Analysis of reference myositis sera and a pool of 10 normal human sera (NHS) by dotblot. RNA precipitated by autoantibodies in myositis sera was spotted on nylon filters and probed with antisense RNA probes to detect anti-Mas, anti-SRP, and anti-Jo-1 ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...